Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report issued on Monday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.37 on Monday. The firm has a market capitalization of $4.51 million, a PE ratio of -0.05 and a beta of 0.43. Oragenics has a 12 month low of $0.25 and a 12 month high of $7.74. The company’s 50 day simple moving average is $0.33 and its 200 day simple moving average is $0.69.

Oragenics Company Profile

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories